Stirling Products Limited (ASX: STI) Signs Agreement For Use Of ST810 For Treating Heaves In Horses Says CEO Dr Calvin London

Share Article

Perth-based biotechnology company Stirling Products Limited (ASX: STI) has signed a collaborative agreement with a Danish company to work on a new drug treatment for horses, in particular the respiratory disease heaves using its ST810 product says CEO Dr Calvin London.

Perth-based biotechnology company Stirling Products Limited (ASX: STI) has signed a collaborative agreement with a Danish company to work on a new drug treatment for horses using ST810 says CEO Dr Calvin London.

Equine HealthCare ApS and Stirling will conduct a joint feasibility study for the introduction of a new treatment for the respiratory disease, heaves.

“This is a true collaborative win/win situation. They have the drug delivery device and we have a potential drug candidate,” said Stirling Managing Director, Dr Calvin London.

Equine HealthCare is a world leader in the diagnosis and delivery of respiratory diseases in horses and sells almost 4,500 units of the Equine Haler™ a year. The Equine Haler™ is an inhalation device, which offers aerosol therapy directly in the airways of the horse.

“R-salbutamol is a purified active ingredient from salbutamol which has previously been shown to have positive effects in treating heaves in horses. We estimate the size of the market for heaves and related respiratory disorders in horses to be up to US$100 million a year,” Dr London said.

The agreement also provides an opportunity for Stirling to introduce the compound ST810 (R-salbutamol) into the European regulatory system with a product that has a relatively short time to market.

“A number of leading international equine veterinarians recognise that inhalation therapy provides a superior delivery system where the drug is delivered directly to the affected organs for maximum effect,” Dr London said.

About Stirling Products:

Stirling Products is commercialising patented animal growth promoters that turn fat into protein and improve feed efficiencies in poultry, sheep, pigs, cattle and fish. These products will play a major role in reducing the global use of antibiotics and steroids for animal growth promotion.

About Heaves:

Heaves is the most severe form of chronic obstructive pulmonary diseases in horses and is triggered by exposure to an array of different allergens in a similar way to asthma in humans. Potential markets include Europe, the United States, Canada and Asia Pacific.

For All Media Enquiries Contact: Managing Director, Dr Calvin London on

T: +618 9480 1480, M: +61 400 204616 or E: calvin.london@stirlingproducts.net

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Thomas Murrell
Visit website